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This study evaluates the ability of the Chlamydia sur-
veillance  system  to  provide  relevant  information  to 
inform prevention and control activities in Sweden. The 
system was evaluated, according to the Guidelines for 
Evaluating  Public  Health  Surveillance  Systems  from 
the  United  States  Centers  for  Disease  Prevention  and 
Control,  using  surveillance  data  from  1997  to  2008. 
We  interviewed  staff  from  the  Swedish  Institute  for 
Communicable  Disease  Control,  the  National  Board 
of Health and Welfare and one county medical officer 
(CMO).  We  conducted  a  survey  among  laboratories, 
CMOs and a sample of clinics. Satisfaction with the sys-
tem was good for 86% of CMOs, all laboratories, and 99% 
of clinics. The interviewed stakeholders considered the 
system to deliver relevant and accurate information that 
is useful for health policy decision making. However, the 
objectives for Chlamydia surveillance should be clearly 
defined in order to adapt the system requirements, sim-
plify data collection and improve timeliness.
Introduction
Chlamydia trachomatis (Ct) is the most common bacte-
rial sexually transmitted infection (STI) in Europe [1]. 
According to the latest report from the European Centre 
for  Disease  Prevention  and  Control  (ECDC),  335,329 
cases were notified in 2008 by 23 Member States of 
the European Union (EU), the European Economic Area 
and the European Free Trade Association (EEA/EFTA), 
with an incidence rate of 150 cases per 100,000. The 
incidence was even higher in the age group of 15–24 
year-olds  where  it  reached  a  rate  of  976  cases  per 
100,000. Underreporting is common and the real inci-
dence in Europe is supposed to be much higher [1].
In Sweden, the absolute number as well as the incidence 
of Ct cases have been rising since 1997 (Figure 1), with 
a sharp increase in 2007 when diagnostic tests became 
available that detected the new Ct variant that had previ-
ously been missed with some of the standard tests [2]. 
The most affected group have been teenagers and young 
adults  between  15  and  29  years  of  age,  particularly 
women. This age group was responsible for most of the 
increase in incidence observed over the years, with little 
change over time in the other age groups. The Ct control 
strategy in Sweden includes free testing and treatment, 
active partner tracing and opportunistic screening, mainly 
of young women (when Chlamydia testing is offered dur-
ing a visit to a gynaecologist or a youth health or STI 
clinic for other reasons (e.g. contraception counselling).
With the number of Ct cases steadily increasing, a reli-
able and functioning surveillance system is paramount 
to follow trends, inform public health action and moni-
tor prevention and control interventions. Although the 
electronic surveillance system used in Sweden for all 
notifiable diseases (SmiNet) has been evaluated con-
cerning the sensitivity and timeliness for four selected 
diseases in the past [3,4], the Ct surveillance system 
has  never  been  formally  evaluated  in  Sweden.  This 
study aimed to determine whether the current Ct sur-
veillance system delivers relevant, accurate and timely 
information  to  those  who  need  it  in  order  to  enable 
adequate prevention and control measures.
Figure 1
Chlamydia trachomatis infections notified per year and 
age group, Sweden 1997-2008*
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Methods
Chlamydia surveillance in Sweden
In Sweden, notification of Ct infection cases started on 
a voluntary basis for laboratories in 1982. Mandatory 
notification for clinicians was introduced in 1988 and 
for laboratories in 2004. Initially the reporting of cases 
was  aggregated  but  case-based  reporting  was  intro-
duced  in  1997  for  clinical  notifications  and  in  2005 
for  laboratory  notifications.  According  to  the  case 
definition for Ct adopted in Sweden [5], all laboratory-
confirmed  cases  have  to  be  reported  to  the  national 
surveillance system SmiNet. Confirmation of the diag-
nosis is made by the 29 laboratories that test for Ct.
The Ct surveillance system is comprehensive, including 
the  entire  Swedish  population,  and  has  two  compo-
nents: case-based reporting and aggregated reporting 
of the number of tests performed annually.
Case-based reporting is made through an electronic sur-
veillance system (SmiNet) which was introduced in 1997 
and upgraded and changed to web-based reporting in 
2004 (SmiNet-2) [6]. Clinics and laboratories are required 
to report individual cases through SmiNet-2 using a web-
based  interface.  Individual  cases  are  reported  anony-
mously  using  a  modified  code  based  on  the  unique 
personal  identification  number  that  all  residents  in 
Sweden  have.  The  modified  code  itself  is  not  unique, 
because reporting of STIs must by law be anonymous. 
Therefore laboratory and clinical notifications cannot be 
linked in the system. For the national surveillance, only 
clinical notifications are taken into account, since one 
case may have more than one laboratory report.
Aggregated  reporting  is  a  parallel  voluntary  surveil-
lance system for laboratories to report the number of 
tests performed for Ct and the number of positives by 
sex and age group. This is reported electronically via 
SmiNet or on paper once a year. Although it is volun-
tary, all laboratories performing Chlamydia testing in 
Sweden report the data.
Data flow
Figure 2 shows the data flow between the different com-
ponents of the Ct surveillance system, from the reporting 
sources to the data recipients. The data are collected at 
clinics and laboratories and entered in SmiNet through a 
web-based interface. The CMOs can access the data on 
cases reported in their own county, and SMI can access 
all the data. A summary of the data obtained from sur-
veillance is published weekly on the SMI website, bian-
nually  in  Epi-Aktuellt  (SMI’s  official  publication)  and 
annually at SMI´s Annual Epidemiological Report. This 
information is then used by SMI, CMOs and the National 
Board of Health and Welfare (SoS) to monitor trends and 
guide public health action concerning Ct.
Evaluation of performance attributes
We followed the Guidelines for Evaluating Public Health 
Surveillance Systems from the United States Centers 
for Disease Prevention and Control (CDC) for the evalu-
ation [7]. We aimed to evaluate the following system 
performance  attributes:  usefulness,  simplicity,  data 
quality,  flexibility,  acceptability,  representativeness, 
timeliness and stability.
Usefulness,  flexibility  and  acceptability  were  evalu-
ated  through  semi-structured  interviews  conducted 
with key staff involved in Ct surveillance and control 
at  the  Swedish  Institute  for  Communicable  Disease 
Control (SMI) and the SoS as well as with the county 
medical  officer  from  Västerbotten  county.  The  CMO 
from Västerbotten county was chosen because of his 
expertise and research experience in Ct infections.
Data quality and timeliness were evaluated analysing 
the surveillance data for the period from 1997 to 2008 
for clinical notifications and for the period from 2005 
to 2008 for laboratory notifications.
We calculated the proportion of completeness for all 
variables,  the  proportion  of  invalid  values  and  the 
median number of days with interquartile range (IQR) 
between the date of laboratory diagnosis and the date 
of notification. In order to assess timeliness we also 
calculated  the  percentage  of  notifications  received 
within 24 hours, 7 days and 30 days of diagnosis (arbi-
trarily selected time spans) for the period from 2005 to 
2008. We restricted the analysis to this period because 
the requirements were changed in 2004 to reporting 
within 24 hours of diagnosis.
Figure 2
Chlamydia surveillance data flow in Sweden
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We considered that the most probable factor that could 
affect the system’s representativeness in Sweden would 
be differences in access to healthcare between the dif-
ferent counties. The number of youth health clinics dif-
fers per county and some counties offer the possibility 
to request a free test through the Internet or even by 
mobile phone message. This can give different degrees 
of access to Ct testing in the different counties, and thus 
affect the representativeness of the Ct surveillance sys-
tem. We calculated the number of youth clinics available 
per 10,000 population aged between 16 and 23 years 
in each county to get a rough estimate of access to Ct 
testing.  The  number  of  youth  clinics  per  county  was 
obtained from the official site for youth health clinics 
(www.umo.se). The population aged between 16 and 23 
years per county was obtained from Statistics Sweden 
(www.scb.se)  using  the  data  for  the  year  2008.  We 
chose this indicator because the majority of infections 
occur in the age group of 16–23 year-olds in Sweden 
and most of these infections are diagnosed and treated 
in youth clinics. We also examined differences between 
the sexes in the number of people screened per year for 
Ct infection to explore how this could affect the repre-
sentativeness of the surveillance system.
Additionally, simplicity, data quality, acceptability, rep-
resentativeness and stability were evaluated through 
self-administered  questionnaires  sent  to  all  county 
medical offices (CMOs, n=21), all laboratories testing 
for Ct (n=29) and a sample of clinics participating in Ct 
surveillance (n=300). The questionnaires were sent by 
post and a reminder was sent by post or e-mail after 
four weeks to the CMOs and laboratories. No reminder 
was  sent  for  the  clinics  due  to  logistics  constraints. 
The sample of clinics was selected randomly among all 
clinics in Sweden that had reported at least 12 cases 
of Ct infection in 2008. We calculated that a sample of 
200 clinics would be required to calculate proportions 
with a 95% confidence interval and a margin of error of 
less than 0.1. With an expected response rate of 70% 
based on previous surveys among healthcare workers 
in Sweden [8-10], we increased our sample by 30% to 
compensate. The final sample was 300 clinics.
Data analysis
The responses from the CMOs and laboratories were 
entered  manually  in  EpiData.  The  questionnaires 
from the clinics were scanned and exported to Excel. 
After data cleaning and validation, data analysis was 
carried out using Stata 10 (StataCorp) and MS Excel. 
Qualitative data obtained from the interviews and from 
open  questions  in  the  questionnaires  were  reviewed 
and organised into specific themes. These were then 
reviewed in relevance to the related attribute.
Results
We  interviewed  two  staff  from  SMI,  five  staff  from 
SoS and one county medical officer. All 21 CMOs, 26 
of 29 laboratories (90%) and 183 of 300 clinics (61%) 
returned the questionnaire.
Purpose of the surveillance system
The overall aim of the Ct surveillance system as part of 
the national surveillance system is to meet the require-
ments of the Swedish Communicable Disease Act [11] in 
order to protect the population against the spread of 
infectious diseases. However, we could not identify any 
documents stating the specific objectives for Ct surveil-
lance. That was a justification to use CDC’s guidelines 
for the evaluation of the surveillance system and not to 
evaluate the system against its objectives. According to 
the staff involved in Chlamydia surveillance the objec-
tives  were:  to  estimate  the  incidence  of  Chlamydia 
infection in Sweden, to monitor trends in notified cases 
by age, sex and reporting county, and to identify poten-
tial risk groups for further preventive interventions.
Usefulness
All the stakeholders interviewed agreed that the data 
collected through surveillance were useful for health 
policy decision making, stimulating research and moni-
toring interventions aimed at controlling and prevent-
ing Ct infection. As a direct result of the analysis and 
interpretation  of  surveillance  data  showing  a  steady 
increase  in  the  number  of  cases  in  recent  years,  a 
new Chlamydia National Action Plan was launched in 
2009 [12]. This plan aims at reducing prevalence of Ct 
infection by 2014 through increased use of condoms 
among teenagers and young adults (15-29 years-old), 
increased  awareness  and  understanding  of  Ct  infec-
tion  in  the  population,  increased  access  to  testing, 
counselling and treatment and improvement in sexual 
education in schools [12]. In addition, there is a KAP 
(Knowledge, Attitudes and Practices) study underway 
among youths in Sweden (UngKAB, Socialstyrelsen) to 
improve understanding of underlying factors influenc-
ing the increase in the number of cases and to identify 
opportunities for prevention and control.
Simplicity
Data collection
The data collected for surveillance has a set of compul-
sory fields and a set of voluntary fields. For the clini-
cal notifications, the following fields are compulsory: 
registration date (assigned automatically by SmiNet), 
diagnosis (disease), type of patient identification (ID) 
used, patient ID, age, sex, county of residence, type 
of  clinic,  reporting  clinic  and  responsible  physician’s 
name.  The  median  time  needed  to  collect  this  infor-
mation in the studied period was 20 minutes (range: 
1–180 minutes). The information needed for the labo-
ratory  notification  is  obtained  from  the  laboratory 
request  form.  The  following  fields  are  compulsory: 
registration date (assigned automatically by SmiNet), 
diagnosis (disease), laboratory, type of report, type of 
patient ID used, patient ID, age, responsible laboratory 
physician, referring clinic and county of the clinic.
Data management 
Once  the  information  is  collected  in  the  clinics,  the 
data must be manually entered into SmiNet (or sent 4 www.eurosurveillance.org
in paper to the CMO). Fifty-three percent of the clin-
ics (96 of 182) reported entering data less than once 
a  week,  while  only  6%  (11  of  182)  did  so  daily.  The 
median time to fill in the form was 5 minutes (range: 
1–30 minutes).
Laboratory  notifications  can  be  done  automatically 
by direct link of the laboratory database to SmiNet or 
manually entering the data into SmiNet. Fifteen of 24 
laboratories  reported  having  automatic  notification. 
The data was entered daily in all of the laboratories 
with automatic reporting and in seven of the nine labo-
ratories with manual reporting.
After  the  notifications  are  entered  into  SmiNet,  they 
must be approved by the CMOs. This was done daily 
by 18 of the 21 CMOs. Twelve CMOs reported checking 
for double reporting using the laboratory number, the 
numeric code or the date of sampling.
Ninety-six  percent  of  the  clinics  (173  of  180)  and  all 
laboratories reported dedicating less than 5 hours per 
week to activities related to surveillance, while 15 of 21 
CMOs reported less than 10 hours.
At SMI, the notifications are reviewed weekly by an epi-
demiologist. Regular contact is maintained with CMOs 
when required.
Flexibility
SmiNet  was  introduced  in  1997  and  upgraded  to 
SmiNet-2 in 2004. Before 2004 all the data was sent 
to the CMOs or SMI to be entered, but since the intro-
duction  of  SmiNet-2  notifications  have  been  entered 
directly by the clinics and laboratories. The notification 
reports in SmiNet for Ct can be easily modified if new 
variables need to be added or unnecessary ones elimi-
nated. However, any changes must be approved by the 
CMOs, SMI and SoS.
Data quality
Perceived data quality
Fifty-seven percent of the clinics (102 of 180)  reported 
never or only occasionally filling in all the information 
requested  in  the  notification  form.  The  main  reason 
given for this was that the requested information was 
considered to be irrelevant for Ct surveillance.
Observed completeness of the data
In the period under evaluation there were 325,925 clini-
cal notifications and 104,642 laboratory notifications. 
The compulsory variables were 100% complete for all 
the years for both types of notifications. Tables 1 and 
2 show the percentages of completeness for selected 
non-compulsory  variables  in  clinical  and  laboratory 
notifications for the time period under evaluation. We 
also examined the percentage of clinical notifications 
with invalid values. For most variables, it was under 
1%.  However,  for  infection  date  and  onset  date,  this 
percentage was as high as 7%.
Acceptability
Eighteen of the 21 CMOs, all the laboratories and 168 
of 169 of the clinics (99%) reported being satisfied or 
Table 1
Completeness of non-compulsory variables (%) in clinical notifications for Chlamydia trachomatis infection, Sweden 
1997–2008                     
NA: not available
Variable 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Date of diagnosis 4 60 85 89 89 92 93 92 95 94 93 92
Type of infection 5 77 78 90 93 97 97 96 92 91 91 90
Reason for examination 4 43 56 56 59 62 62 64 70 81 87 87
Infection date 1 9 18 20 28 27 27 32 45 38 37 29
Onset date 1 7 11 12 13 14 14 13 15 18 17 16
Country of infection 9 47 67 79 85 89 90 92 93 92 91 91
Place of infection 5 37 55 54 56 62 64 66 66 64 60 58
Place of onset 1 11 16 17 19 21 23 25 32 33 32 33
Route of transmission 8 71 92 94 94 96 98 98 96 95 95 89
Country of birth 0 0 0 0 0 0 0 0 6 23 29 34
Reporting laboratory NA NA NA NA NA NA NA 1 31 60 76 77
Laboratory number NA NA NA NA NA NA NA 1 18 59 77 76
Table 2
Completeness of non-compulsory variables (%) in 
laboratory notifications for Chlamydia trachomatis 
infection, Sweden 2005–2008       
             
Variable 2005 2006 2007 2008
Sex 99 100 100 100
Date of receipt of sample 79 80 87 86
Date of testing 99 99 98 97
Sample material 98 94 98 98
Test number 86 96 97 975 www.eurosurveillance.org
very satisfied with the Ct surveillance system. CMOs 
and laboratories mentioned as the main disadvantage 
of  the  system  the  impossibility  to  use  the  personal 
identification  number  in  the  reporting,  while  clinics 
reported the lack of access to the report once is sent 
as the main disadvantage.
Representativeness
Perceived representativeness
On  the  questionnaires,  12  CMOs  reported  having  an 
estimation  of  the  degree  of  underreporting  in  their 
counties. They estimated it to be between 0 and 10% 
with a median of 4%. In the interviews, the stakehold-
ers estimated that they had 5% underreporting based 
on the difference in the number of clinical and labora-
tory notifications.
Observed representativeness
In Sweden, there are between one and 10 youth clinics 
per 10,000 population aged between 16 and 23 years 
per county, with a median of three. There was no cor-
relation  between  number  of  youth  clinics  per  10,000 
16-23  year-olds  and  Chlamydia  incidence  in  the  same 
age group (Spearman’s rank correlation test, p=0.8812).
We  also  examined  differences  between  sexes  in  the 
number of tests performed annually for Ct infection for 
the period for which such information was available. 
Between  the  years  2000  and  2008  almost  3  million 
tests  were  performed  among  women  compared  with 
just under 1 million among men. Although the number 
of  tests  increased  over  the  years,  especially  among 
men,  there  were  still  2.6  times  more  tests  per  year 
among women than among men in 2008. However, the 
rate of positive tests was higher among men.
Timeliness
Perceived timeliness
In the interviews, publication of the data on the SMI 
website  once  a  week  was  considered  to  be  timely 
enough. However, publication only every six months of 
the aggregated reporting of the number of tests was 
considered to be insufficient.
Observed timeliness
The median delay between the date of the laboratory 
test and the date of notification to SmiNet was 5 days 
(interquartile range (IQR): IQR 3-7 days) for laboratory 
notifications and 11 days (IQR 6-20 days) for clinical noti-
fications for the whole study period (Figures 3 and 4).
Overall,  1%  of  all  laboratory  notifications  during  the 
study period were notified within 24 hours, 85% within 
Figure 3
Median delay time (in days) between date of diagnosis and 
date of laboratory notification of Chlamydia trachomatis 
infections, Sweden 2005–2008 (n=104,642)
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Figure 4
Median delay time (in days) between the date of diagnosis and the date of clinical notifications of Chlamydia trachomatis 
infections, Sweden 1997–2008 (n=325,925)
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7 days and 99% within 30 days. For clinical notifica-
tions the figures were 9%, 45% and 91%, respectively.
Stability
Five per cent of the clinics, 10% of the laboratories and 
81% of the CMOs reported having technical problems 
with  SmiNet.  The  frequency  of  these  problems  was 
once a year or less for 97% of the clinics and 75% of 
the laboratories, and at least once a month for 88% 
of CMOs. The problems most frequently reported were 
system  freeze  and  problems  with  login.  When  asked 
about  the  use  of  SmiNet  technical  support,  54%  of 
the clinics, 58% of the laboratories and all the CMOs 
reported always receiving it when required. 
Discussion 
We  aimed  to  evaluate  the  Ct  surveillance  system  in 
Sweden by describing the system and measuring the 
usefulness,  simplicity,  data  quality,  acceptability, 
representativeness,  timeliness  and  stability  of  the 
system. We could not identify any documents stating 
the specific objectives for the Ct surveillance system. 
Defining the objectives of the system would be crucial 
to  establish  whether  the  current  system  is  adequate 
for Ct surveillance and better define the improvements 
necessary for the system to deliver the relevant infor-
mation needed for action. 
An important challenge with the surveillance system in 
Sweden is the anonymous notification of cases which 
makes automatic linkage between clinical and labora-
tory  notifications  impossible.  Due  to  this  complexity 
of linkage it was decided to consider only the clinical 
notifications with epidemiological information for case 
counting.  The  laboratory  notifications,  mandatory 
according to the Communicable Disease Act, are there-
fore not used for routine surveillance (but for could be 
used for the research). This means that we may miss 
laboratory-confirmed cases for which a clinical notifica-
tion does not exist. This lack of unique personal identi-
fication number (which would allow linking clinical and 
laboratory  notifications)  was  perceived  as  an  impor-
tant disadvantage of the Ct surveillance system by all 
stakeholders.
The simplicity of the Ct surveillance system was per-
ceived as adequate by the respondents. System users 
considered  the  data  flow  as  good  (fast  enough  and 
technically  less  problematic  than  manual  reporting) 
between  the  different  levels  (clinics/laboratories, 
CMOs and SMI). The number of compulsory variables 
needed to fill in a clinical or laboratory notification is 
low. However, the total number of variables in the clini-
cal notification is high. The variation between clinics 
in the time needed to collect all the information for the 
clinical  notification  may  be  related  to  how  thorough 
they are in their data collection, although we did not 
assess this aspect. For the laboratories, the introduc-
tion  of  automatic  reporting  linked  to  the  databases 
has  made  the  reporting  easier  and  less  resource-
intensive. Simplicity of use and speed were the main 
advantages of the system perceived by CMOs, clinics 
and laboratories.
The  information  gathered  through  surveillance  was 
considered to be useful by health policy decision mak-
ers.  All  interviewed  stakeholders  reported  using  the 
information  gathered  through  surveillance  to  decide 
on  public  health  action,  such  as  the  implementation 
of a new Chlamydia National Action Plan in 2009 [12]. 
However, there were suggestions to collect more infor-
mation on the social background and sexual behaviour 
of  cases.  This  would  help  to  identify  particular  risk 
groups  and  to  better  target  prevention  activities  but 
would be time- and resource-consuming. Finland has a 
sentinel surveillance network for STIs where detailed 
information  concerning  risk  behaviour  is  collected 
through a self-administered anonymous questionnaire 
in 12 clinics around the country [13]. A similar approach 
could be explored in Sweden. 
The Ct surveillance system is flexible and modifying the 
notification forms is possible and relatively easy to do. 
However,  agreement  between  all  stakeholders  (SMI, 
SoS and CMOs) is needed before any changes can be 
implemented, which can result in delays. Data quality 
was considered to be ‘good’ for compulsory variables 
and for voluntary variables perceived as important for 
Ct  surveillance.  Variables  like  infection  date,  onset 
date, place of onset, place of infection and country of 
birth had a low completeness rate. They were consid-
ered to be ‘irrelevant’ and it was suggested to remove 
them from the notification because this information is 
rarely available.
The general acceptability of the Ct surveillance system 
is high. Most CMOs, laboratories and clinics are satis-
fied or very satisfied with the system.
Representativeness  was  very  difficult  to  evaluate.  Ct 
surveillance comprises all laboratory-confirmed cases 
in Sweden. However, there is no information on the real 
prevalence of the infection among the Swedish popu-
lation, so it is very difficult to evaluate the number of 
unreported cases or the number of undiagnosed cases. 
The interviewed CMOs and the SMI estimated under-
reporting to be around 5% based on the discrepancy 
between the number of laboratory and clinical notifica-
tions. All stakeholders interviewed agreed that the real 
incidence was probably higher than reported although 
there are no prevalence studies for Ct in Sweden to com-
pare it with. According to the stakeholders, the trends 
obtained  through  the  surveillance  system  should  be 
considered as accurate. Although there is no data on 
Ct prevalence in Sweden and Ct incidence is underre-
ported (due to many asymptomatic and untested per-
sons), general trends are considered to mirror reality 
quite well.
The  number  of  tests  performed  among  women  was 
higher  than  among  men  in  all  studied  years  since 
2000. However, the positivity rate was higher among 7 www.eurosurveillance.org
men.  Rather  than  a  shortcoming  of  the  surveillance 
system itself, this could indicate differences in health 
seeking  behaviour  among  men,  or  that  prevention 
activities  like  opportunistic  screening  are  more  tar-
geted at women. We believe that surveillance system 
is mirroring the real distribution of Chlamydia cases 
in the population by age group, with underrepresen-
tation of cases among men due to the reasons men-
tioned above.
The  timeliness  of  case  reporting  and  data  publica-
tion was adequate, and it improved during the period 
evaluated. However, only 1% of laboratory notifications 
and 9% of clinical notifications were notified within 24 
hours of diagnosis as required by the Communicable 
Diseases  Act.  The  weekly  updates  of  Ct  surveillance 
data on the SMI website was considered timely enough 
by all stakeholders. From a surveillance point of view, 
the notification period could be extended to one week 
to  match  the  frequency  of  reporting.  This  could  be 
improved  by  implementing  automated  data  reporting 
from the laboratories, similar to what is already done 
with  the  case-based  reporting.  However,  this  would 
require the laboratories to invest in the development 
of programmes for automated data transfer, which can 
take time to implement.
The system stability was perceived as ‘good’ with few 
technical  problems  reported  and  efficient  technical 
support when required.
In  conclusion,  the  Ct  surveillance  system  in  Sweden 
delivers  relevant  and  accurate  data  to  inform  pub-
lic  health  action.  However,  the  system  could  be 
improved  further  by  implementing  the  following 
recommendations:
•	 Establish  clear  objectives  for  Ct  surveillance  in 
order to adapt the current system to the needs of 
stakeholders;
•	 Equate  Ct  with  other  notifiable  diseases  ena-
bling  reporting  with  the  personal  identification 
number to avoid case duplication and evaluation of 
reinfections;
•	 Adapt the clinical and laboratory notification forms 
specifically for Ct eliminating unnecessary variables 
in order to simplify data collection and improve data 
quality, acceptability and timeliness;
•	 Extend  automatic  reporting  to  all  laboratories  to 
increase timeliness.
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